Pelthos Therapeutics to Present at 38th Annual ROTH Conference

Rhea-AI Summary

Pelthos Therapeutics (NYSE American: PTHS) announced that CEO Scott Plesha will speak in a fireside chat at the 38th Annual ROTH Conference on March 23, 2026 at 3:00 p.m. PT. A live webcast will be available on the company investor site and replayed for 90 days.

Market Context

This announcement adds another investor-relations touchpoint, following recent conference participat...

Analysis

This announcement adds another investor-relations touchpoint, following recent conference participation, financing arrangements, and the Xeglyze acquisition. The fireside chat on March 23, 2026 offers management a platform to update on ZELSUVMI commercialization and broader strategy. Investors may contextualize this against the company’s up to $50 million debt facility, the effective $200,000,000 shelf registration, and prior product acquisitions when assessing future funding needs and execution milestones.

Key Figures

Conference edition: 38th Annual ROTH Conference Event date: March 23, 2026 Presentation time: 3:00 p.m. Pacific Time +1 more

4 metrics

Conference edition 38th Annual ROTH Conference Event where CEO will speak

Event date March 23, 2026 Scheduled fireside chat at ROTH

Presentation time 3:00 p.m. Pacific Time Time of ROTH fireside chat

Webcast replay period 90 days Replay availability after the event

Historical Context

5 past events · Latest: Mar 09 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 09	Earnings date announcement	Neutral	-0.3%	Set date and call details for Q4 and full-year 2025 results.
Feb 23	Conference participation	Neutral	+5.0%	Announced CEO presentation at Oppenheimer healthcare conference with webcast access.
Jan 13	Debt financing	Positive	-1.3%	Secured up to $50 million term loan facility to support product launches.
Jan 05	Product acquisition	Positive	-9.0%	Acquired FDA-approved Xeglyze lice treatment with no ongoing milestone or royalty payments.
Dec 23	Board expansion	Positive	-1.8%	Appointed experienced finance executive Andrew Einhorn to the board and key committees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows several strategic or financing updates followed by negative price reactions, suggesting the stock has often traded lower on ostensibly constructive news.

Recent Company History

Over the past few months, Pelthos reported multiple corporate developments. It scheduled Q4 and full-year 2025 results for March 19, 2026, announced prior conference participation on February 26, 2026, and secured a senior secured term loan facility of up to $50 million on January 13, 2026. The company also acquired FDA‑approved Xeglyze for $1.8 million and added Andrew Einhorn to the board on December 23, 2025. Today’s ROTH conference appearance continues this pattern of investor outreach and strategic positioning updates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DURHAM, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that CEO Scott Plesha will participate in a fireside chat at the 38^th Annual ROTH Conference on March 23, 2026 at 3:00 p.m. Pacific Time.

Investors interested in arranging one-on-one meetings should contact their ROTH representative.

A live webcast of the fireside chat will be available on the News & Events page in the Investors section of the Company’s website at https://pelthos.com. A replay of the webcast will be available for 90 days following the event.

About Pelthos Therapeutics
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI™ (berdazimer) topical gel, 10.3%, the company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat Molluscum contagiosum. The company’s portfolio of assets also includes Xepi® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and Xeglyze® (abametapir), a topical treatment for head lice. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.

Contacts
Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Media:
KWM Communications
Kellie Walsh
pelthos@kwmcommunications.com
(914) 315-6072

FAQ

When will Pelthos Therapeutics (PTHS) present at the 38th Annual ROTH Conference?

Pelthos will present on March 23, 2026 at 3:00 p.m. Pacific Time. According to Pelthos, CEO Scott Plesha will participate in a fireside chat, with a live webcast accessible on the company investor website for remote viewers.

How can investors watch the Pelthos (PTHS) fireside chat webcast on March 23, 2026?

Investors can watch the live webcast on the Pelthos investor site. According to Pelthos, the webcast is available via the News & Events page and can be streamed live at the scheduled 3:00 p.m. PT start time.

Will Pelthos (PTHS) provide a replay of the ROTH Conference presentation and for how long?

Yes, a replay will be available for 90 days after the event. According to Pelthos, the recorded fireside chat will remain on the company website for three months following the March 23, 2026 presentation.

Who is the Pelthos (PTHS) executive speaking at the ROTH Conference fireside chat?

CEO Scott Plesha will participate in the fireside chat on March 23, 2026. According to Pelthos, Plesha will represent the company during the 3:00 p.m. PT session to discuss corporate developments and strategy.

How can investors arrange one-on-one meetings with Pelthos (PTHS) at the ROTH Conference?

Investors should contact their ROTH representative to arrange one-on-one meetings. According to Pelthos, meeting scheduling is handled through ROTH, so investors should coordinate directly with their ROTH contact before the March 23, 2026 event.